This overview draws on seven studies commissioned by the UK's Department for International Development. After providing some background, it considers the implications of stronger intellectual property protection for access to medicines; the prospects for supply in emerging and under-served markets; and makes recommendations for increasing access
This study describes current drug regulation and registration processes in selected countries, in order to understand how they affect the quality and availability of medicines in developing countries. It puts forward policy recommendations as to how systems can more efficiently allow appropriate quality drugs to be marketed and examines the emerging challenges and requirements posed by compulsory licensing, drugs for neglected diseases, anti-retroviral (ARV) and anti-tuberculosis (TB) drugs